Quadrivalent Influenza Vaccine Prevents Illness and Reduces Healthcare Utilization Across Diverse Geographic Regions During Five Influenza Seasons A Randomized Clinical Trial

Autor: Dbaibo G, Amanullah A, Claeys C, Izu A, Jain VK, Kosalaraksa P, Rivera L, Soni J, Yanni E, Zaman K, Acosta B, Ariza M, Arroba Basanta ML, Bavdekar A, Carmona A, Cousin L, Danier J, Diaz A, Diez-Domingo J, Dinleyici EC, Faust SN, Garcia-Sicilia J, Gomez-Go GD, Gonzales MLA, Hacimustafaoglu M, Hughes SM, Jackowska T, Kant S, Lucero M, Mares Bermudez J, Martinón-Torres F, Montellano M, Prymula R, Puthanakit T, Ruzkova R, Sadowska-Krawczenko I, Szymanski H, Ulied A, Woo W, Schuind A, Innis BL, Flu4VEC Study Group

Publikováno v: PEDIATRIC INFECTIOUS DISEASE JOURNAL
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica
instname

Background: We evaluated an inactivated quadrivalent influenza vaccine (IIV4) in children 6-35 months of age in a phase III, observer-blind trial. Methods: The aim of this analysis was to estimate vaccine efficacy (VE) in preventing laboratory-confir

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::bdd6e4d3259a006f27dd494cf9f40c48
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=4575

COVID-19 Antigen Testing: Better than We Know?

Autor: Tomaskova H, Jakub Mrázek, Jezo E, Kloudova A, Homza M, Janosek J, Prymula R, Svagera Z, Zelená H

Publikováno v: SSRN Electronic Journal.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::07a17f120d890f96724a1fc85a11e800
https://doi.org/10.2139/ssrn.3758022

Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial

Autor: Iro, MA, Snape, MD, Voysey, M, Jawad, S, Finn, A, Heath, PT, Bona, G, Esposito, S, Diez-Domingo, J, Prymula, R, Odueyungbo, A, Toneatto, D, Dull, P, Pollard, AJ, European Men B Vaccine Study Group

Publikováno v: Iro, M A, Snape, M D, Voysey, M, Jawad, S, Finn, A, Heath, P T, Bona, G, Esposito, S, Diez-Domingo, J, Prymula, R, Odueyungbo, A, Toneatto, D, Dull, P & Pollard, A J 2017, ' Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial ', Vaccine, vol. 35, no. 2, pp. 395-402 . https://doi.org/10.1016/j.vaccine.2016.11.009

Background4CMenB is immunogenic in infants and toddlers. We assessed persistence of human complement serum bactericidal activity (hSBA) following a fourth dose administered at 12, 18 or 24 months and characterised the antibody response to a fifth dos

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d863f64d7aaa17c7c582f08d7ef2bddf

Corrigendum to 'Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial' [Vaccine 35 (2017) 395-402]

Autor: Iro, MA, Snape, MD, Voysey, M, Jawad, S, Finn, A, Heath, PT, Bona, G, Esposito, S, Diez-Domingo, J, Prymula, R, Odueyungbo, A, Toneatto, D, Dull, P, Pollard, AJ, European Men B Vaccine Study Group

Publikováno v: Vaccine. 35(24)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::eec972447eba3e38330f9b9539ceaae7
http://ora.ox.ac.uk/objects/uuid:

Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules

Autor: Sadarangani, M, Sell, T, Iro, MA, Snape, MD, Voysey, M, Finn, A, Heath, PT, Bona, G, Esposito, S, Diez-Domingo, J, Prymula, R, Odueyungbo, A, Toneatto, D, Pollard, AJ, European MenB Vaccine Study Group

Publikováno v: CANADIAN MEDICAL ASSOCIATION JOURNAL
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)

BACKGROUND: One schedule for the capsular group B meningococcal vaccine 4CMenB is 2 doses that are administered 2 months apart for children aged 12-23 months, with a booster dose 12-24 months later. Our objective was to provide data on persistence of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::6ae9619318b8c0af4cdd6abffcebcbb0
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=2300